|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum neopterin and beta2-mieroglobulin concentrations as'prognostic markers'of AIDS显示文摘 | Halota W Jaruga B Pawlowska M | 2002 | Pol Merkuriusz Lek2002，13，： | 1 |
| 2 | Depres- sive symptoms and cognitive dysfunction in patients with hepatitis C treated with interferon -e and ribavirine显示文摘 | DROZDZ W BORKOWSKA A HALOTA W | 2008 | Arch Psychiat Psychother2008，1，： | 1 |
| 3 | Serum IL-2 and sIL- 2R concentration in children with chronic hepatitis B显示文摘 | Pawlowska M Halota W Smukahka E otal | 2005 | Pol Merkur Lekarski2005，18，103： | 1 |
| 4 | HBV DNA suppression during entecavir treat- ment in previously treated children with chronic hepati- tis B显示文摘 | PAWEOWSKA M HALOTA W SMUKALSKA E | 2012 | Eur J Clin Microbiol Infect Dis2012，31，： | 1 |
| 5 | Serum neopterin and β2-microglobulin concentrations as'prognostic markers' of AIDS显示文摘 | Halota W Jaruga B Pawlowska M | 2002 | Pol Merkur Lekarski2002，13，： | 1 |
| 6 | Plasma selenium concentration glutathione peroxidase and glutathione S-transferase activities in patients with chronic liver diseases显示文摘 | Czuczejko J Halota W Zachara BA | 2002 | Pol Merkuriusz Lek2002，13，76： | 1 |
| 7 | Interferon-induced thyroiditis during treatment of chronic hepatitis C 显示文摘 | Kozielewicz D Halota W | 2012 | Endokrynol Pol2012，63，1： | 1 |
| 8 | Plasma selenium concentration glutathione peroxidase and glutathione S-transferase activities in patients with chronic liver diseases 显示文摘 | Czuczejko J Halota W Zachara B A | 2002 | Pol Merkttriusz Lek2002，13，76： | 1 |
| 9 | HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B 显示文摘 | PAWLOWSKA M HALOTA W SMUKALSKA E | 2012 | Eur J Clin Mi- crobiol Infect Dis2012，31，4： | 1 |
| 10 | Serum IL-2 and sI2R COncentrafionin childrenwith chronic hepatitis B 显示文摘 | Pawlowska M Halota W Smukalska E ct al | 2005 | PolMerkurLkarski2005，18，103： | 1 |
| 11 | Serum IL-2 and SIL-2R concentration in children with chronic hepatitis B显示文摘 | Pawlowska M Halota W Smukalska E | 2005 | Pol Merkur Lekarski2005，8，103： | 1 |
| 12 | Virologic re- sponse to treatment with pegylated interferon alfa-2h and ribavirin chric hepatitis C in children显示文摘 | Pawlowska M Pilarczyk M Halota W | 2008 | Hepatology2008，48，4： | 1 |
| 13 | Plasma selenium concentration glutathione peroxidase and glutathione Sransferase activities in patients with chronic liver diseases显示文摘 | Czuczejko J Halota W Zachara BA | 2002 | Pol Merkur Lekarski2002，13，76： | 1 |
| 14 | Prospects for anti-HIV vaccine显示文摘 | Halota W Pawlowska M | 2006 | HIV AIDS Rev2006，5，1： | 1 |
| 15 | Factors influencing the failure of interferon-free therapy for chronic hepatitis C:Data from the Polish EpiTer-2 cohort study显示文摘BACKGROUND The introduction of direct-acting antiviral drugs into clinical practice has revolutionized the treatment of chronic hepatitis C,making it highly effective and safe for patients.However,few researchers have analyzed the factors causing therapy failure in some patients.AIM To analyze factors influencing the failure of direct antiviral drugs in the large,multicenter EpiTer-2 cohort in a real-world setting.METHODS The study cohort consisted of patients with chronic hepatitis C treated at 22 Polish centers from 2016-2020.Data collected from the online EpiTer-2 database included the following:hepatitis C virus(HCV)genotype,stage of fibrosis,hematology and liver function parameters,Child-Turcotte-Pugh and Model for End-stage Liver Disease scores,prior antiviral therapy,concomitant diseases,and drugs used in relation to hepatitis B virus(HBV)and/or human immunodeficiency virus(HIV)coinfections.Adverse events observed during the treatment and follow-up period were reported.Both standard and machine learning methods were used for statistical analysis.RESULTS During analysis,12614 patients with chronic hepatitis C were registered,of which 11938(mean age:52 years)had available sustained virologic response(SVR)data[11629(97%)achieved SVR and 309(3%)did not].Most patients(78.1%)were infected with HCV genotype 1b.Liver cirrhosis was diagnosed in 2974 patients,while advanced fibrosis(F3)was diagnosed in 1717 patients.We included patients with features of hepatic failure at baseline[ascites in 142(1.2%)and encephalopathy in 68(0.6%)patients].The most important host factors negatively influencing treatment efficacy were liver cirrhosis,clinical and laboratory features of liver failure,history of hepatocellular carcinoma,and higher body mass index.Among viral factors,genotype 3 and viral load also exerted an influence on treatment efficacy.Classical statistical analysis revealed that treatment ineffectiveness seemed to be influenced by the male sex,which was not confirmed by the multivariate analysis using the machine learning algorithm(random forest).Coinfection with HBV(including patients with on-treatment reactivation of HBV infection)or HIV,extrahepatic manifestations,and renal failure did not significantly affect the treatment efficacy.CONCLUSION In patients with advanced liver disease,individualized therapy(testing for resistance-associated variants and response-guided treatment)should be considered to maximize the chance of achieving SVR. | Ewa Janczewska Mateusz Franciszek Kołek Beata Lorenc Jakub Klapaczyński Magdalena Tudrujek-Zdunek Marek Sitko Włodzimierz Mazur Dorota Zarębska-Michaluk Iwona Buczyńska Dorota Dybowska Agnieszka Czauż-Andrzejuk Hanna Berak RafałKrygier Jerzy Jaroszewicz Jolanta Citko Anna Piekarska Beata Dobracka Łukasz Socha Zbigniew Deroń Łukasz Laurans Jolanta Białkowska-Warzecha Olga Tronina Brygida Adamek Krzysztof Tomasiewicz Krzysztof Simon Malgorzata Pawłowska Waldemar Halota Robert Flisiak | 2021 | World Journal of Gastroenterology2021，27，18： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员